With the CHS-114 data set to debut at SITC 2025, spotlighting its cytolytic anti-CCR8 mechanism and early immune remodeling signals, Coherus Oncology Inc. (CHRS) is aligning scientific visibility with commercial expansion. LOQTORZI continues to gain traction in nasopharyngeal carcinoma, and with trial readouts expected in 1H 2026 and Q3 earnings due November 6, the company is entering a catalyst-heavy stretch that could reshape its immuno-oncology footprint.
CHS-114 Spotlight
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.